Sarepta Therapeutics (SRPT) Update

Clinical Progress:

Sarepta has recently reported early clinical data from its siRNA pipeline targeting two rare neuromuscular diseases: Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1) and Myotonic Dystrophy Type 1 (DM1). These programs leverage Sarepta’s proprietary TRiM™ platform, which uses an avβ6 integrin-targeted ligand to deliver siRNA therapies directly to muscle tissue, overcoming traditional delivery challenges.

• SRP-1001 (FSHD1): Early Phase 1/2 data show dose-dependent increases in plasma and muscle siRNA concentrations with no dose-limiting toxicities. The therapy demonstrated robust target engagement, with over 90% suppression of DUX4-regulated genes, which are implicated in muscle degeneration. A 33% reduction in creatine kinase, a biomarker of muscle injury, was observed, indicating potential therapeutic benefit. Safety profile is favorable with mostly mild to moderate adverse events.

• SRP-1003 (DM1): Similarly, SRP-1003 showed dose-dependent plasma exposure and superior muscle delivery compared to other siRNA approaches. Early biomarker data indicate approximately 50% reduction in DMPK mRNA, the toxic RNA driving DM1 pathology. Safety data are reassuring, with no dose-related serious adverse events linked to the drug. One unrelated fatal arrhythmia was reported, consistent with known disease risks.

Platform Advantages:

• The avβ6 integrin targeting allows for higher muscle uptake and longer dosing intervals compared to transferrin receptor (TfR1)-based approaches.

• The TRiM™ platform’s siRNA chemistry enhances stability, reduces immunogenicity, and improves potency.

• No saturation of muscle siRNA uptake observed, supporting potential for dose escalation to maximize efficacy.

Pipeline and Milestones:

• Sarepta has five siRNA programs in clinical development, including SRP-1001, SRP-1003, SRP-1005 (Huntington’s disease), and others targeting pulmonary and neurodegenerative diseases.

• Upcoming milestones include multiple ascending dose (MAD) data for SRP-1001 and SRP-1003 expected in the second half of 2026.

• Dosing for Huntington’s disease program to commence in Q2 2026, with proof-of-biology data anticipated in H1 2027.

Analysis and Price Target Reiteration

Based on the clinical data and Sarepta’s strategic positioning, we reiterate our positive outlook and price target for SRPT, supported by the following:

• Differentiated Technology: Sarepta’s TRiM™ platform offers a best-in-class delivery mechanism that achieves superior muscle targeting and knockdown of disease-causing mRNAs, addressing a key limitation in RNA therapies for neuromuscular diseases.

• Early Clinical Validation: The Phase 1/2 data for SRP-1001 and SRP-1003 demonstrate promising biomarker responses and a strong safety profile, which bodes well for future efficacy readouts and regulatory progress.

• Large Unmet Medical Need: Both FSHD1 and DM1 are debilitating, life-limiting diseases with no approved disease-modifying treatments, representing significant market opportunities.

• Robust Pipeline and Growth Potential: Sarepta’s expanding siRNA portfolio across multiple rare diseases, combined with its leadership in Duchenne muscular dystrophy, positions the company for sustained growth.

• Upcoming Catalysts: The MAD data readouts in H2 2026 and further clinical progress in Huntington’s disease and other programs provide multiple near-term value inflection points.

Risks: As with all early-stage biotech programs, risks include clinical trial outcomes, regulatory approvals, competitive landscape, and execution challenges. The early data, while encouraging, require confirmation in larger and longer studies.

Sarepta Therapeutics is advancing a promising siRNA platform with early clinical data supporting its potential to deliver best-in-class therapies for rare neuromuscular diseases. The company’s differentiated delivery technology, strong biomarker signals, and favorable safety profile underpin our confidence in its pipeline. We reiterate our positive stance and price target on SRPT, anticipating significant value creation as clinical programs progress through 2026 and beyond.

You can read our series on SRPT here: